In the last decade, the clinical microbiology industry witnessed significant technological advancements and robust product development. These advancements are transforming the way in which clinical microbiology testing techniques are utilized for clinical diagnosis of diseases (such as respiratory diseases, bloodstream infections, gastrointestinal diseases, and sexually transmitted diseases).
North America and Europe are mature markets for clinical microbiology products. However, emerging regions such as Asia-Pacific (including China India, Brazil, and Mexico) are expected to become the new revenue-generating pockets in the clinical microbiology market in the next five years. The North American clinical microbiology market is expected to hold the largest market share in 2016. However, the Asia-Pacific clinical microbiology market it is poised to grow at the highest CAGR owing to the increasing number of hospitals and clinical diagnostic laboratories in India and China; expanding research capabilities for the development of innovative and affordable clinical microbiology testing procedures across India, China, and Japan; and rising incidences of infectious diseases.
Europe is expected to hold the second-largest share of the global clinical microbiology market in 2016. The prominent market position of the European clinical microbiology market is due to factors such as the rising acceptance of genome-based diagnostic techniques by healthcare professionals, supportive government policies that ease public accessibility to diagnostic assay procedures (including clinical microbiology), large number of clinical microbiology procedures performed annually across the region, presence of a large number of biotechnology and molecular diagnostic companies, rapid growth in the aging population, and growing incidence of infectious diseases.
Rapid microbial diagnostic techniques are increasingly being preferred for performing microbiology testing across the world owing to their technological benefits (as compared to traditional microbiology testing techniques). Based on disease area, the clinical microbiology market is segmented into respiratory diseases, bloodstream infections, gastrointestinal diseases, sexually transmitted diseases, urinary tract infections, periodontal diseases, and other diseases (cardiovascular disease, central nervous system infections, connective tissue & joint diseases, and skin diseases, among others). The respiratory disease segment is expected to grow at a higher CAGR owing to the large patient population for respiratory diseases and rising prevalence of tuberculosis across developing countries.
Leading players in the clinical microbiology market include bioMerieux S.A. (France), Danaher Corporation (U.S.), Becton, Dickinson and Company (U.S.), Cepheid (U.S.) Abbott Laboratories (U.S.), Bio-Rad Laboratories (U.S.), F. Hoffman-La Roche Ltd. (Switzerland), Alere Inc. (U.S.), Bruker Corporation (U.S.), and Hologic, Inc. (U.S.).
